Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00079820 | Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults | PHASE1 | COMPLETED | 110 | — | — | Apr 1, 2004 | Oct 1, 2006 | Jan 13, 2014 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112 |
| B | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-8) with no Challenge |
| C | PLACEBO_COMPARATOR | Placebo |
| D | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112 |
| E | EXPERIMENTAL | MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112 |
| Name | Type | Description |
|---|---|---|
| ACAM3000 MVA Vaccine | BIOLOGICAL | Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days |
Inclusion Criteria: Subjects must meet the following to be eligible for the study: * adult males or females who provided informed consent for the study. * adults 18 and 31 years (inclusive). * good general health, * female subjects must not be pregnant or lactating and be on appropriate contracept...